Ahammune Biosciences
Pune, India· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Ahammune Biosciences develops targeted small molecule therapies for chronic skin diseases, with a lead program for vitiligo that has completed Phase 1 trials.
Immunology
Technology Platform
Small molecule platform targeting deregulated cellular pathways in chronic skin diseases to restore homeostatic states, with a focus on autoimmune mechanisms.
Opportunities
Significant unmet need in vitiligo treatment market with potential for first-in-class therapy; platform technology could expand to other autoimmune skin conditions like psoriasis or alopecia areata.
Risk Factors
Clinical development risks for novel mechanism; competition from larger dermatology-focused pharmaceutical companies; regulatory challenges for first-in-class autoimmune skin therapies.
Competitive Landscape
Competes against symptomatic vitiligo treatments like topical corticosteroids and calcineurin inhibitors; potential competition from other biotechs targeting autoimmune pathways; differentiation through first-in-class mechanism and potential for permanent relief.